MedTrace Logo

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age

NCT07730450 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-08-07

No results posted yet for this study

Summary

The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age.

This study is seeking participants who:

* are medically stable
* have not had a recent COVID-19 infection
* have not had a recent vaccination
* do not have medical conditions that increase their risk of complications from COVID-19

All participants in this study will randomly receive 1 injection into their arm of either:

* BNT162b2 vaccine which targets COVID-19 and is selected for the 2026-2027 COVID-19 season, or
* Tdap vaccine which targets tetanus, diphtheria, and pertussis (whooping cough).

The study team and participants will not know which injection they receive. We will evaluate safety and SARS-CoV-2 spike protein levels in people receiving each of these vaccines.

Participants will be in the study for about 12 months.

Conditions

  • COVID-19 Vaccines

Interventions

BIOLOGICAL

BNT162b2 Vaccine

Participants will receive a single injection containing variant-adapted BNT162b2 on Day 1.

BIOLOGICAL

Tdap Vaccine

Participants will receive a single injection containing Tdap on Day 1.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-23
Primary Completion
2027-08-20
Completion
2027-08-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07730450 on ClinicalTrials.gov